Symbols

BIOX

Bioceres Crop·NASDAQ

--(--)

BIOX fundamentals

BIOX Q1 2026 Earnings

Bioceres Crop (BIOX) released its earnings on Nov 13, 2025: revenue was 77.50M (YoY -16.93%), missed estimates; EPS was -0.1183 (YoY -40.33%), missed estimates.

Revenue / YoY

77.50M

-16.93%

EPS / YoY

-0.1183

-40.33%

Report date

Nov 13, 2025

BIOX Earnings Call Summary for Q1,2026

Margin transformation success: 650bps gross margin expansion to 47% despite 17% revenue decline, driven by high-margin seed treatments and cost cuts.
Profitability rebound: EBITDA up 61% to $13.6M, with $5.9M SG&A savings and working capital efficiency improvements.
Strategic focus on profitability: Exiting low-margin businesses, reducing debt to 6.8x EBITDA, and maintaining liquidity amid Argentina macro challenges.
Key risks: Argentina's slow recovery, delayed Europe biostimulant sales, and ongoing debt disputes.

Earnings

EPS

Revenue

Revenue & Expenses

BIOX has released its 2026 Q2 earnings report, with revenue of 73.81M, reflecting a YoY change of -25.30%, and net profit of -182.47M, showing a YoY change of -30248.24%. The Sankey diagram below clearly presents BIOX's revenue sources and cost distribution.

Key Indicators

Bioceres Crop (BIOX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Bioceres Crop (BIOX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Bioceres Crop (BIOX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Bioceres Crop (BIOX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown